We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+38.9%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.13B
AUM Growth
+$1.33B
Cap. Flow
+$252M
Cap. Flow %
3.09%
Top 10 Hldgs %
38.33%
Holding
153
New
32
Increased
35
Reduced
44
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$111M
3
ESRX
Express Scripts Holding Company
ESRX
+$60.7M
4
ABBV icon
AbbVie
ABBV
+$52.2M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$48.2M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$78.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$61.6M
3
CELG
Celgene Corp
CELG
+$61.1M
4
INCY icon
Incyte
INCY
+$58.6M
5
UNH icon
UnitedHealth
UNH
+$51.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.16%
2 Technology 0.09%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
126
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.96M 0.04%
+196,000
New +$2.21M
BLRX
127
BioLineRX
BLRX
$12.3M
$2.53M 0.03%
1,892
– –
CERS icon
128
CALL
Cerus
CERS
$577M
$2.4M 0.03%
+500,000
New +$3.21M
QLTI
129
DELISTED
QLT Inc
QLTI
$1.67M 0.02%
300,000
-150,000
-33% -$929K
MNKD icon
130
PUT
MannKind Corp
MNKD
$1.21B
$1.61M 0.02%
+80,000
New +$2.27M
EXAS
131
PUT
DELISTED
Exact Sciences
EXAS
$1.42M 0.02%
100,000
+13,800
+16% +$186K
ALBO
132
DELISTED
Albireo Pharma Inc
ALBO
$1.09M 0.01%
13,333
-4,915
-27% -$447K
ZGNX
133
CALL
DELISTED
Zogenix, Inc.
ZGNX
$875K 0.01%
+38,450
New +$1.25M
AMRN
134
Amarin Corp
AMRN
$298M
$724K 0.01%
20,000
-10,000
-33% -$372K
ACAD icon
135
Acadia Pharmaceuticals
ACAD
$4.46B
– –
-135,000
Closed -$3.37M
BAX icon
136
Baxter International
BAX
$12.8B
– –
-449,204
Closed -$17M
ELV icon
137
Elevance Health
ELV
$82.7B
– –
-429,000
Closed -$39.6M
ILMN icon
138
CALL
Illumina
ILMN
$29.3B
– –
-102,800
Closed -$11.1M
INCY icon
139
CALL
Incyte
INCY
$25.2B
– –
-70,000
Closed -$3.54M
TECH icon
140
Bio-Techne
TECH
$11.2B
– –
-200,000
Closed -$4.73M
TEVA icon
141
PUT
Teva Pharmaceuticals
TEVA
$39.3B
– –
-200,000
Closed -$152K
UTHR icon
142
United Therapeutics
UTHR
$25.9B
– –
-55,000
Closed -$6.22M
ISEE
143
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-34,500
Closed -$1.12M
HSP
144
DELISTED
HOSPIRA INC
HSP
– –
-85,000
Closed -$3.51M
CHDX
145
DELISTED
CHINDEX INTL INC
CHDX
– –
-36,000
Closed -$627K
FRX
146
CALL
DELISTED
FOREST LABORATORIES INC
FRX
– –
-150,000
Closed -$9.01M
QGENF
147
DELISTED
QIAGEN NV
QGENF
– –
-1,927,000
Closed -$45.9M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2014 Portfolio in Review

As of Q1 2014, OrbiMed held 153 positions worth $8.13B, up 20% from $6.8B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $252M of net new capital in Q1 2014, opening 32 new positions and adding to 35 existing holdings. Its largest new stake was Eli Lilly: 543,000 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $78.6M trimmed.

  • OrbiMed's largest Q1 2014 buy was Eli Lilly: 543,000 shares worth $32M.
  • OrbiMed added most to Allergan Inc in Q1 2014, an estimated $182M increase.
  • OrbiMed's biggest Q1 2014 reduction was Aetna Inc, cutting an estimated $78.6M.
  • OrbiMed fully exited QIAGEN NV in Q1 2014, selling an estimated $45.9M.
  • OrbiMed's ten largest holdings make up 38% of its $8.13B portfolio in Q1 2014.
  • OrbiMed opened 32 new positions and closed 13 in Q1 2014.
  • OrbiMed's portfolio value rose 20% quarter-over-quarter to $8.13B.

Based on OrbiMed's 13F filing for Q1 2014, filed 15 May 2014.